Waterfall with bar chart over the top Waterfall
orange diamonds

What is PEMAZYRE® (pemigatinib)?

PEMAZYRE monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.1a

FGFR2 fusion positivity status must be known prior to initiation of PEMAZYRE therapy. Assessment for FGFR2 fusion positivity in tumour specimens should be performed with an appropriate diagnostic test.1

Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3. It inhibits FGFR phosphorylation and signalling and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements.1

aThis medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and the Summary of Product Characteristics will be updated as necessary.1

1. PEMAZYRE® (pemigatinib). Summary of Product Characteristics: Sections 4.1, 4.2 and 5.1. September 2023 (data cutoff: 08 July 2021).

Medical book

ESMO guideline recommendations

Discover more about ESMO guideline recommendations for patients with CCA.

Discover more

ESMO Guideline
DNA Helix


Learn more about the clinical data on PEMAZYRE.

Discover more

Medical book

FGFR2 fusion testing

Discover about FGFR2 fusions in patients with CCA.

Discover more

Clock and pill

Dosing and administration

Learn more about the dosing and administration schedule of PEMAZYRE.

Discover more

Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

PEMAZYRE self-directed learning

A self-directed learning material on PEMAZYRE to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.

Learn about PEMAZYRE